Cargando…

Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study

BACKGROUND: Primary pancreatic lymphoma (PPL) is a rare pancreatic neoplasm that is difficult to diagnose. PPL has a vastly different prognosis and treatment regimen than other pancreatic tumors; therefore, accurate diagnosis is vital. In this article, we describe the characteristic presentation, en...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Eric A., Benson, Mark E., Guda, Nalini, Pfau, Patrick R., Frick, Terrence J., Gopal, Deepak V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247529/
https://www.ncbi.nlm.nih.gov/pubmed/25485269
http://dx.doi.org/10.4103/2303-9027.144530
_version_ 1782346654565793792
author Johnson, Eric A.
Benson, Mark E.
Guda, Nalini
Pfau, Patrick R.
Frick, Terrence J.
Gopal, Deepak V.
author_facet Johnson, Eric A.
Benson, Mark E.
Guda, Nalini
Pfau, Patrick R.
Frick, Terrence J.
Gopal, Deepak V.
author_sort Johnson, Eric A.
collection PubMed
description BACKGROUND: Primary pancreatic lymphoma (PPL) is a rare pancreatic neoplasm that is difficult to diagnose. PPL has a vastly different prognosis and treatment regimen than other pancreatic tumors; therefore, accurate diagnosis is vital. In this article, we describe the characteristic presentation, endoscopic ultrasound (EUS) features, and the role of fine-needle aspiration (FNA) in the diagnosis of PPL compared with pancreatic adenocarcinoma. MATERIALS AND METHODS: This was a retrospective case-control study of 11 patients diagnosed with PPL via EUS between 2002 and 2011. The clinical and EUS features of the cases were then compared with age-matched controls with adenocarcinoma in a 1:3 ratio. RESULTS: There were 11 patients with PPL and 33 with adenocarcinoma. At last follow-up, 7 of 11 PPL patients were alive, and 3 of 33-adenocarcinoma patients were alive (P < 0.001). The most common presenting symptoms for PPL were pain 73%, weight loss 45%, and jaundice 18%, while patients with adenocarcinoma presented with pain 52% (P = 0.3), weight loss 30% (P = 0.47) and jaundice 76% (P = 0.001). The EUS appearance was similar in the two groups in that ultrasound imaging of the pancreas lesions tended to be hypoechoic and heterogenous, but the PPL group was more likely to have peripancreatic lymphadenopathy (LAD) (64% vs. 18%, P = 0.008) and were larger (4.8 cm × 5.3 cm vs. 3.2 cm × 3.1 cm, P < 0.001). The PPL group was less likely to have vascular invasion (18% vs. 55%, P = 0.045) and less likely to be found in the head of the pancreas (36% vs. 85%, P = 0.004). FNA and cytology (without flow cytometry [FC]) made the diagnosis in 28% of PPL patients compared with 91% of adenocarcinoma patients (P = 0.002). In the PPL group, 7 of 11 FNA samples were sent for FC. If FC was added, then the diagnosis of PPL was increased to 100%. CONCLUSIONS: Compared with adenocarcinoma, pancreatic lymphoma has a better prognosis, is less likely to present with jaundice and less likely to have vascular invasion. PPL is more likely to be located outside the head of the pancreas and to include peripancreatic LAD, and is less likely to be diagnosed with cytology. The diagnostic accuracy of FNA for PPL is improved greatly with the addition of FC.
format Online
Article
Text
id pubmed-4247529
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42475292014-12-05 Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study Johnson, Eric A. Benson, Mark E. Guda, Nalini Pfau, Patrick R. Frick, Terrence J. Gopal, Deepak V. Endosc Ultrasound Original Article BACKGROUND: Primary pancreatic lymphoma (PPL) is a rare pancreatic neoplasm that is difficult to diagnose. PPL has a vastly different prognosis and treatment regimen than other pancreatic tumors; therefore, accurate diagnosis is vital. In this article, we describe the characteristic presentation, endoscopic ultrasound (EUS) features, and the role of fine-needle aspiration (FNA) in the diagnosis of PPL compared with pancreatic adenocarcinoma. MATERIALS AND METHODS: This was a retrospective case-control study of 11 patients diagnosed with PPL via EUS between 2002 and 2011. The clinical and EUS features of the cases were then compared with age-matched controls with adenocarcinoma in a 1:3 ratio. RESULTS: There were 11 patients with PPL and 33 with adenocarcinoma. At last follow-up, 7 of 11 PPL patients were alive, and 3 of 33-adenocarcinoma patients were alive (P < 0.001). The most common presenting symptoms for PPL were pain 73%, weight loss 45%, and jaundice 18%, while patients with adenocarcinoma presented with pain 52% (P = 0.3), weight loss 30% (P = 0.47) and jaundice 76% (P = 0.001). The EUS appearance was similar in the two groups in that ultrasound imaging of the pancreas lesions tended to be hypoechoic and heterogenous, but the PPL group was more likely to have peripancreatic lymphadenopathy (LAD) (64% vs. 18%, P = 0.008) and were larger (4.8 cm × 5.3 cm vs. 3.2 cm × 3.1 cm, P < 0.001). The PPL group was less likely to have vascular invasion (18% vs. 55%, P = 0.045) and less likely to be found in the head of the pancreas (36% vs. 85%, P = 0.004). FNA and cytology (without flow cytometry [FC]) made the diagnosis in 28% of PPL patients compared with 91% of adenocarcinoma patients (P = 0.002). In the PPL group, 7 of 11 FNA samples were sent for FC. If FC was added, then the diagnosis of PPL was increased to 100%. CONCLUSIONS: Compared with adenocarcinoma, pancreatic lymphoma has a better prognosis, is less likely to present with jaundice and less likely to have vascular invasion. PPL is more likely to be located outside the head of the pancreas and to include peripancreatic LAD, and is less likely to be diagnosed with cytology. The diagnostic accuracy of FNA for PPL is improved greatly with the addition of FC. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4247529/ /pubmed/25485269 http://dx.doi.org/10.4103/2303-9027.144530 Text en Copyright: © Endoscopic Ultrasound http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Johnson, Eric A.
Benson, Mark E.
Guda, Nalini
Pfau, Patrick R.
Frick, Terrence J.
Gopal, Deepak V.
Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study
title Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study
title_full Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study
title_fullStr Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study
title_full_unstemmed Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study
title_short Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: A case-control study
title_sort differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: a case-control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247529/
https://www.ncbi.nlm.nih.gov/pubmed/25485269
http://dx.doi.org/10.4103/2303-9027.144530
work_keys_str_mv AT johnsonerica differentiatingprimarypancreaticlymphomafromadenocarcinomausingendoscopicultrasoundcharacteristicsandflowcytometryacasecontrolstudy
AT bensonmarke differentiatingprimarypancreaticlymphomafromadenocarcinomausingendoscopicultrasoundcharacteristicsandflowcytometryacasecontrolstudy
AT gudanalini differentiatingprimarypancreaticlymphomafromadenocarcinomausingendoscopicultrasoundcharacteristicsandflowcytometryacasecontrolstudy
AT pfaupatrickr differentiatingprimarypancreaticlymphomafromadenocarcinomausingendoscopicultrasoundcharacteristicsandflowcytometryacasecontrolstudy
AT frickterrencej differentiatingprimarypancreaticlymphomafromadenocarcinomausingendoscopicultrasoundcharacteristicsandflowcytometryacasecontrolstudy
AT gopaldeepakv differentiatingprimarypancreaticlymphomafromadenocarcinomausingendoscopicultrasoundcharacteristicsandflowcytometryacasecontrolstudy